Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

1.7K
Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
1.7K
Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

233
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
233
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of Two Pulsed Field Ablation Systems for Atrial Fibrillation: One-Year Outcomes From a Multicenter Registry.

Journal of cardiovascular electrophysiology·2026
Same author

Multicenter analysis of device-detected atrial fibrillation burden reduction after antiarrhythmic drug initiation.

Heart rhythm O2·2026
Same author

Performance and Safety of the Extravascular Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy.

JACC. Clinical electrophysiology·2026
Same author

Postoperative Atrial Arrhythmias After Lung Transplantation: A Single Center Analysis of Risk Factors, Management, and Outcomes.

Clinical transplantation·2026
Same author

"Response by Kalluri et al. to Letter Regarding Article," "Catheter Ablation: Evolution and Efficiencies".

Journal of cardiovascular electrophysiology·2026
Same author

Recurrent Myocarditis After COVID Vaccination in a Patient With FLNC Mutation Undergoing Treatment for Lymphoma.

JACC. Case reports·2026

Related Experiment Video

Updated: Apr 30, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

27.5K

The totally subcutaneous implantable defibrillator.

John Rhyner1, Bradley P Knight2

  • 1Division of Cardiology, Department of Medicine, Northwestern University, 303 E Chicago Ave, Chicago, IL 60611, USA.

Cardiology Clinics
|May 6, 2014
PubMed
Summary

The subcutaneous implantable cardioverter-defibrillator (S-ICD) offers a new way to prevent sudden cardiac arrest. This S-ICD therapy effectively treats dangerous heart rhythms with fewer complications than traditional devices.

Keywords:
Cardiac arrestClinical trialS-ICDSubcutaneous implantable cardioverter-defibrillatorTherapy

More Related Videos

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.9K
Computed Tomography (CT) Guided Implantation of a Totally Implantable Venous Access Port (TIVAP) through Subclavian Vein
05:51

Computed Tomography (CT) Guided Implantation of a Totally Implantable Venous Access Port (TIVAP) through Subclavian Vein

Published on: January 13, 2026

395

Related Experiment Videos

Last Updated: Apr 30, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

27.5K
Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.9K
Computed Tomography (CT) Guided Implantation of a Totally Implantable Venous Access Port (TIVAP) through Subclavian Vein
05:51

Computed Tomography (CT) Guided Implantation of a Totally Implantable Venous Access Port (TIVAP) through Subclavian Vein

Published on: January 13, 2026

395

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Medical Devices

Background:

  • Sudden cardiac arrest (SCA) remains a significant health concern.
  • Traditional transvenous implantable cardioverter-defibrillators (ICDs) carry risks like infection and lead failure.
  • A novel S-ICD system offers an alternative approach to transvenous ICDs.

Purpose of the Study:

  • To evaluate the safety and efficacy of the subcutaneous implantable cardioverter-defibrillator (S-ICD).
  • To assess the S-ICD's ability to manage malignant tachyarrhythmias.
  • To highlight the benefits of the S-ICD configuration compared to transvenous systems.

Main Methods:

  • The S-ICD system involves a subcutaneous pulse generator and electrode, avoiding venous access.
  • Clinical trials were conducted to assess device performance.
  • The study involved sensing, discrimination, and conversion of induced and spontaneous ventricular arrhythmias.

Main Results:

  • The S-ICD system effectively sensed and discriminated ventricular tachyarrhythmias.
  • The device successfully converted episodes of ventricular tachycardia and ventricular fibrillation.
  • Complication rates associated with the S-ICD implantation were minimal.

Conclusions:

  • The S-ICD is a viable therapeutic option for patients at risk of sudden cardiac arrest.
  • This S-ICD configuration preserves venous access and reduces risks of infection and lead failure.
  • The S-ICD provides reliably effective therapy for malignant tachyarrhythmias.